Skip to content

Clinical effect of Naoxue oral liquid on patients with spontaneous cerebral hemorrhage: a single-center, open, non-randomized controlled study

Clinical effect of Naoxue oral liquid on patients with spontaneous cerebral hemorrhage: a single-center, open, non-randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005320
Enrollment
Unknown
Registered
2021-09-17
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spontaneous intracerebral hemorrhage

Interventions

A2:After surgical treatment but did not take Naoxueshu oral liquid.
A1:Without surgical treatment and without taking Naoxue Shu oral liquid
B2:After surgical intervention and taking Naoxue Shuoral liquid
B1:Take Naoxue Shuoral liquid without surgical treatment
A2A1B2B1

Sponsors

North China University of Science and Technology Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 1. Patients who were confirmed by magnetic resonance imaging ((MRI)) and computerized tomography ((CT)) and met the criteria for the diagnosis and treatment of SICH approved in the AHA/ASA guidelines were selected. 2.the amount of supratentorial bleeding = 30ml, the displacement of midline does not exceed 5mm, and the amount of subependental bleeding = 10ml. 3. The age is between 18 and 80 years old. 4. Select SICH patients within one week of onset 5. The NIHSS score is between 2 and 20. 6. Obtain the informed consent of the patient.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.the amount of supratentorial bleeding > 30ml, the shift of midline exceeded 5mm, and the amount of subependental bleeding > 10ml. 2. Severe dysarthria, hearing impairment, cognitive impairment and other reasons lead to the inability of patients to cooperate with the scale assessment. two 3. Patients with loss of consciousness and disturbance of consciousness 4. Because of the insufficiency of important organs such as heart, liver and kidney, the researchers do not think it is suitable to participate in this study. 5. A person with a serious mental illness.

Design outcomes

Primary

MeasureTime frame
Serious adverse events;Severity of brain edema;Volume of hematomas;

Secondary

MeasureTime frame
Liver function;Blood routine;Coagulation function;Neural function evaluation;Renal function;

Countries

China

Contacts

Public ContactChen Tong

North China University of Science and Technology Affiliated Hospital

ct.1973@163.com15032915731

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026